Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + Osimertinib vs Osimertinib in First-Line EGFR-Mutated Advanced NSCLC
NCT06838273Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Progression-Free Survival at 36 months. Started Feb 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06838273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838273.